The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection

NCT04774107 PHASE1 COMPLETED

Primary Objective: To determine the P1101 pharmacokinetic (PK) profile at the single dose of 400 μg.

Details

Lead sponsor	PharmaEssentia
Phase	PHASE1
Status	COMPLETED
Enrolment	17
Start date	Thu Nov 26 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Jul 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Hepatitis C, Chronic

Interventions

• P1101 + Ribavirin

Countries

Taiwan